Suven Life Sciences — 360° view

Suven Life Sciences, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹1.00 crore and a net loss of ₹107 crore for the September 2026 quarter.

Suven Life Sciences (NSE: SUVEN) closed at ₹269.40 on 20 Nov 2026, up 52.1% over the past year. Its market capitalisation is ₹7,612 crore.

Share price
₹269.40 (20 Nov 2026)
Market cap
₹7,612 Cr (20 Nov 2026)
Revenue
₹1 Cr (September 2026 quarter)
Net profit
₹-107 Cr (September 2026 quarter)
ROCE
-79.5% (FY26)
ROE
-81.5% (FY26)
Book value
₹16.0 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹403.35 / ₹124.11 (20 Nov 2026)
1-year return
52.1% (to 20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Research, Analytics & Technology
Symbol
NSE: SUVEN

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.